Core Viewpoint - The increasing levels of blood lipids and the prevalence of dyslipidemia among Chinese individuals highlight the need for better management of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) [1][2][3] Group 1: Importance of LDL-C Management - LDL-C is identified as a major contributor to high blood lipids and a significant risk factor for ASCVD, emphasizing the importance of lowering LDL-C levels to reduce morbidity and mortality associated with cardiovascular diseases [1][2] - Experts advocate for a targeted and stratified approach to blood lipid management, stressing the need for public awareness and education regarding the significance of monitoring LDL-C levels [1][2] Group 2: Lifestyle and Treatment Recommendations - Lifestyle modifications, including dietary control and physical activity, are crucial as approximately two-thirds of LDL-C comes from external sources [2][3] - Regular monitoring and risk assessment of LDL-C levels are essential, especially for high-risk populations, who may require more stringent control and treatment of underlying conditions like hypertension and diabetes [2][3] Group 3: Misconceptions and Long-term Treatment - There is a prevalent misconception among patients that achieving target LDL-C levels means discontinuing medication, which can lead to adverse cardiovascular events [3][4] - Continuous and scientifically guided lipid-lowering therapy is vital for stabilizing LDL-C levels and preventing cardiovascular incidents, particularly in patients with existing ASCVD [3][4] Group 4: Current Treatment Landscape - The treatment rates and achievement rates for lipid-lowering therapy among ASCVD patients need improvement, with many still relying on traditional statin medications [4] - While statins are effective, some patients may have contraindications, necessitating the use of non-statin alternatives for optimal LDL-C management [4]